Iovance Biotherapeutics is trading 10.58% up at $8.84, apparently driven by melanoma-biotech enthusiasm after positive Phase 3 vaccine results from Moderna and Merck, rather than a new Iovance announcement.
- Extended its 13.66% gain on August 19.
- Amtagvi-driven second-quarter results and analyst price-target increases provided earlier-August support.
- Biotech is down 2.47%; no fresh catalyst was identified for August 20, 2026, making this move sector-driven.